Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer
Open Access
- 2 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (7) , ofaa172
Abstract
In phase 3 trials, inactivated VZV vaccine (ZVIN) was well tolerated and efficacious against herpes zoster (HZ) in autologous HSC transplant (auto-HSCT) recipients and patients with solid tumor malignancies receiving chemotherapy (STMc) but did not reduce HZ incidence in patients with hematologic malignancies (HM). Here, we describe ZVIN immunogenicity from these studies. Patients were randomized to ZVIN or placebo (4 doses). Immunogenicity was assessed by glycoprotein ELISA (gpELISA) and VZV IFN-γ enzyme-linked immunospot (ELISPOT) assay in patients receiving all 4 doses without developing HZ at the time of blood sampling. Estimated geometric mean fold rise ratios (ZVIN/placebo) by gpELISA and IFN-y ELISPOT ~28 days postdose 4 were 2.02 (95% CI, 1.53–2.67) and 5.41 (3.60–8.12) in auto-HSCT recipients; 1.88 (1.79–1.98) and 2.10 (1.69–2.62) in patients with STMc; and not assessed and 2.35 (1.81–3.05) in patients with HM. ZVIN immunogenicity was directionally consistent with clinical efficacy in auto-HSCT recipients and patients with STMc even though HZ protection and VZV immunity were not statistically correlated. Despite lack of clinical efficacy in patients with HM, ZVIN immunogenicity was observed in this population. Immunological results did not predict vaccine efficacy in these 3 populations.Keywords
Funding Information
- Merck Sharp and Dohme United Kingdom
This publication has 29 references indexed in Scilit:
- Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trialThe Lancet Infectious Diseases, 2019
- Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster VaccinesMMWR. Morbidity and Mortality Weekly Report, 2018
- Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplantCurrent Medical Research and Opinion, 2017
- Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical TrialClinical Infectious Diseases, 2017
- Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive ReviewAdvances in Therapy, 2016
- A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic TransplantationTransplantation and Cellular Therapy, 2013
- Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).2008
- Recommendations for the Management of Herpes ZosterClinical Infectious Diseases, 2007
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster VirusClinical and Diagnostic Laboratory Immunology, 2001